Katharina Bischof

  • Consultant / Postdoc; MD, PhD
  • +47 22 78 17 52

Room: K04:061 

Short bio

After graduation from Medical University Vienna, Austria, Dr. Bischof underwent  residency training in Obstetrics and Gynecology in Vienna and Bergen. In 2014, she enrolled the postgraduate PhD program at the Centre for Cancer Biomarkers at University of Bergen.

Her research background covers translational research in ovarian and endometrial cancer as well as preclinical model development. In 2019, she joined the department of Gynecologic Oncology at the Norwegian Radium Hospital where she is working as a consultant under ESGO certified training.

Besides her clinical activity, she is engaged in clinical studies and committed to biomedical research. She is a member of ENYGO, ESGO, NSGO, Norwegian Medical Association and Oesterreichische Aerztekammer.

 

Publications 2024

Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol, 19 (1), 81-98
DOI 10.1002/1878-0261.13726, PubMed 39245677

Bischof K, Holth A, Bassarova A, Davidson B (2024)
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
Pathol Res Pract, 266, 155787
DOI 10.1016/j.prp.2024.155787, PubMed 39709875

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Dos Santos MV, Holth A, Bischof K, Davidson B (2023)
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Clin Exp Metastasis, 41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113

Publications 2020

Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ et al. (2020)
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
Cancer Epidemiol Biomarkers Prev, 30 (1), 217-228
DOI 10.1158/1055-9965.EPI-20-0739, PubMed 33144283

Kleinmanns K, Bischof K, Anandan S, Popa M, Akslen LA, Fosse V, Karlsen IT, Gjertsen BT, Bjørge L, McCormack E (2020)
CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
EBioMedicine, 56, 102782
DOI 10.1016/j.ebiom.2020.102782, PubMed 32454401

Publications 2019

Bischof K, Knappskog S, Hjelle SM, Stefansson I, Woie K, Salvesen HB, Gjertsen BT, Bjorge L (2019)
Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
Sci Rep, 9 (1), 5244
DOI 10.1038/s41598-019-41706-z, PubMed 30918304

Buckley MA, Woods NT, Tyrer JP, Mendoza-Fandino G, Lawrenson K, Hazelett DJ, Najafabadi HS, Gjyshi A, Carvalho RS, Lyra PC, Coetzee SG, Shen HC, Yang AW, Earp MA, Yoder SJ, Risch H, Chenevix-Trench G, Ramus SJ, Phelan CM, Coetzee GA, Noushmehr H, Hughes TR, Sellers TA, Goode EL, Pharoah PD et al. (2019)
Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus
Cancer Res., 79 (3), 467-481
DOI 10.1158/0008-5472.CAN-17-3864

Publications 2018

Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L (2018)
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma
BMC Cancer, 18 (1), 684
DOI 10.1186/s12885-018-4591-3, PubMed 29940909

Publications 2016

Cuellar-Partida G, Lu Y, Dixon SC, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R et al. (2016)
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes
Hum Genet, 135 (7), 741-56
DOI 10.1007/s00439-016-1663-9, PubMed 27075448

Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L (2016)
The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer
PLoS One, 11 (6), e0158208
DOI 10.1371/journal.pone.0158208, PubMed 27352023

Ong JS, Cuellar-Partida G, Lu Y, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Anne Doherty J, Anne Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N et al. (2016)
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Int J Epidemiol, 45 (5), 1619-1630
DOI 10.1093/ije/dyw207, PubMed 27594614

Publications 2015

Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR, Australian Ovarian Cancer Study, International Endogene Consortium (IEC), Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Wicklund KG, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T et al. (2015)
Shared genetics underlying epidemiological association between endometriosis and ovarian cancer
Hum Mol Genet, 24 (20), 5955-64
DOI 10.1093/hmg/ddv306, PubMed 26231222

Scroll to top